Please use this identifier to cite or link to this item: http://doi.org/10.25358/openscience-7362
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKorb, Christina-
dc.contributor.authorZwiener, Isabella-
dc.contributor.authorLorenz, Katrin-
dc.contributor.authorMirshahi, Alireza-
dc.contributor.authorPfeiffer, Norbert-
dc.contributor.authorStoffelns, Bernhard-
dc.date.accessioned2022-07-12T07:24:42Z-
dc.date.available2022-07-12T07:24:42Z-
dc.date.issued2013-
dc.identifier.urihttps://openscience.ub.uni-mainz.de/handle/20.500.12030/7376-
dc.description.abstractBACKGROUND: To identify risk factors for being a "reduced responder" to ranibizumab treatment in a clinical setting in patients with neovascular age-related macular degeneration. METHODS: This retrospective study included 165 eyes of 165 consecutive patients with choroidal neovascularisation secondary to neovascular, age-related macular degeneration. Eyes were treated with three intravitreal injections of ranibizumab, followed by PRN (pro re nata) dosing thereafter. All patients were reevaluated every four weeks and then followed for six months. Reduced responders were defined as patients with a loss in visual acuity of at least 1 visual acuity line at the last follow-up and/or persistent intraretinal or subretinal fluid or detectable choroidal neovascularisation at the last follow-up, compared to baseline. RESULTS: Overall, 58 out of 165 eyes (35.2%) were considered to be reduced responders to treatment at the end of follow-up. The initial CNV size at baseline was correlated with the risk of being a reduced responder at the end of follow-up (p = 0.017). CONCLUSION: We identified the initial lesion size as a predictor for a reduced response to treatment in this study. Patients with a large initial lesion size should be thoroughly informed about the possible poorer response to the intravitreal treatment.en_GB
dc.description.sponsorshipDFG, Open Access-Publizieren Universität Mainz / Universitätsmedizinde
dc.language.isoengde
dc.rightsCC BY*
dc.rights.urihttps://creativecommons.org/licenses/by/2.0/*
dc.subject.ddc610 Medizinde_DE
dc.subject.ddc610 Medical sciencesen_GB
dc.titleRisk factors of a reduced response to ranibizumab treatment for neovascular age-related macular degeneration : evaluation in a clinical settingen_GB
dc.typeZeitschriftenaufsatzde
dc.identifier.doihttp://doi.org/10.25358/openscience-7362-
jgu.type.dinitypearticleen_GB
jgu.type.versionPublished versionde
jgu.type.resourceTextde
jgu.organisation.departmentFB 04 Medizinde
jgu.organisation.number2700-
jgu.organisation.nameJohannes Gutenberg-Universität Mainz-
jgu.rights.accessrightsopenAccess-
jgu.journal.titleBMC ophthalmologyde
jgu.journal.volume13de
jgu.pages.alternativeArt. 84de
jgu.publisher.year2013-
jgu.publisher.nameBioMed Centralde
jgu.publisher.placeLondonde
jgu.publisher.urihttp://dx.doi.org/10.1186/1471-2415-13-84de
jgu.publisher.issn1471-2415de
jgu.organisation.placeMainz-
jgu.identifier.pmid24359591-
jgu.subject.ddccode610de
opus.date.modified2018-07-31T10:00:12Z-
opus.subject.dfgcode00-000-
opus.organisation.stringFB 04: Medizin: Institut für Med. Biometrie, Epidemologie und Informatikde_DE
opus.organisation.stringFB 04: Medizin: Augenklinik und Poliklinikde_DE
opus.identifier.opusid25282-
opus.importsourcepubmed-
opus.institute.number0424-
opus.institute.number0446-
opus.metadataonlyfalse-
opus.type.contenttypeKeinede_DE
opus.type.contenttypeNoneen_EN
opus.affiliatedKorb, Christina-
opus.affiliatedZwiener, Isabella-
opus.affiliatedLorenz, Katrin-
opus.affiliatedPfeiffer, Norbert-
opus.affiliatedStoffelns, Bernhard-
jgu.publisher.doi10.1186/1471-2415-13-84de
jgu.organisation.rorhttps://ror.org/023b0x485
Appears in collections:DFG-OA-Publizieren (2012 - 2017)

Files in This Item:
  File Description SizeFormat
Thumbnail
risk_factors_of_a_reduced_res-20220710214207306.pdf345.36 kBAdobe PDFView/Open